TaiMed Biologics (4147)

Currency in TWD
62.40
0.00(0.00%)
Delayed Data·
4147 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
62.2063.30
52 wk Range
47.0082.80
Key Statistics
Bid/Ask
69.10 / 69.40
Prev. Close
88
Open
62.9
Day's Range
62.2-63.3
52 wk Range
47-82.8
Volume
-
Average Volume (3m)
1.88M
1-Year Change
-20.2046%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4147 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
180.00
Upside
+188.46%
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Biotechnology industry

TaiMed Biologics News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 180.00
(+188.46% Upside)

Earnings

Latest Release
Aug 20, 2026
EPS / Forecast
-0.27 / -0.23
Revenue / Forecast
155.84M / 156M
EPS Revisions
Last 90 days

4147 Income Statement

Compare 4147 to Peers and Sector

Metrics to compare
4147
Peers
Sector
Relationship
P/E Ratio
−124.1x−2.1x−0.3x
PEG Ratio
−2.940.110.00
Price/Book
4.7x3.6x2.6x
Price / LTM Sales
27.8x31.9x3.1x
Upside (Analyst Target)
185.3%0.0%48.5%
Fair Value Upside
Unlock32.1%6.3%Unlock

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
10.65M3.90%655.85M
Other Institutional Investors
90.78M33.23%5.59B
Public Companies & Retail Investors
171.78M62.88%10.58B
Total
273.2M100.00%16.83B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
National Development Fund, Executive Yuan14.62%39,932,0002,459,811
Huei Hong Investment Co., Ltd.6.63%18,115,8951,115,939

FAQ

What Is the TaiMed Biologics (4147) Stock Price Today?

The TaiMed Biologics stock price today is 62.40 TWD.

What Stock Exchange Does TaiMed Biologics Trade On?

TaiMed Biologics is listed and trades on the Taipei Exchange.

What Is the Stock Symbol for TaiMed Biologics?

The stock symbol for TaiMed Biologics is "4147."

What Is the TaiMed Biologics Market Cap?

As of today, TaiMed Biologics market cap is 17.05B TWD.

What Is TaiMed Biologics's Earnings Per Share (TTM)?

The TaiMed Biologics EPS (TTM) is -0.51.

When Is the Next TaiMed Biologics Earnings Date?

TaiMed Biologics will release its next earnings report on Nov 18, 2026.

From a Technical Analysis Perspective, Is 4147 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has TaiMed Biologics Stock Split?

TaiMed Biologics has split 1 times.

What is the current trading status of TaiMed Biologics (4147)?

As of Aug 20, 2026, TaiMed Biologics (4147) is trading at a price of 62.40 TWD, with a previous close of 88.00 TWD. The stock has fluctuated within a day range of 62.20 TWD to 63.30 TWD, while its 52-week range spans from 47.00 TWD to 82.80 TWD.

What Is TaiMed Biologics (4147) Price Target According to Analysts?

The average 12-month price target for TaiMed Biologics is 180.00 TWD, with a high estimate of 180 TWD and a low estimate of 180 TWD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +188.46% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.